Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

Back to Agenda

Session 8: Hot Topics

Session Chair(s)

Patrik Andersson, PHD

Principal Scientist, Discovery Safety Specialist

AstraZeneca R&D, Sweden

The Hot Topics session will provide an overview of three areas that will provide clarity and likely influence the way of working with oligo projects. 1. An overview of the draft ICH S13 draft guideline on nonclinical safety of oligonucleotides that shortly after the meeting will be published for public consultation; 2. How will the regulatory roadmaps for New Approach Methodologies (NAMs) influence oligo R&D and 3. How can use of AI be applied to oligo therapeutics to increase throughput and success rate of oligo projects.

Learning Objective : At the conclusion of this session, participants should be able to:
Mention key themes in the draft ICH S13 guideline on nonclinical safety for oligos
Discuss specific situations where a NAMs approach could be applied to an oligo project
Suggest potential areas in the oligo project Drug Discovery and Development value chain where application AI could add significant value

Speaker(s)

ICH S13

Representative Invited

BfArM, Germany

NAMs